Genmab - ADR

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 16, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO ® in the U.S.), as reported by Johnson & Johnson were USD 2,692 million in the first quarter of 2024. Net trade sales were USD 1,464 million in the U.S. and USD 1,228 million in the rest of the world.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

ProfoundBio, a Seattle-based biotech firm developing drugs to treat ovarian and endometrial cancers, will be acquired by publicly traded Danish drugmaker Genmab in a $1.

Biotech giant Genmab to acquire Seattle company ProfoundBio in $1.8B deal

Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.

Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio

Danish drugmaker Genmab A/S (GMAB) said Wednesday that it is buying privately held U.S. biotech firm ProfoundBio Inc. for $1.8 billion in cash as it expands its pipeline of cancer treatments.

Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio

Danish biotech Genmab has agreed to buy U.S. cancer drug maker ProfoundBio for $1.8 billion, the two companies said on Wednesday.

Denmark's Genmab to acquire ProfoundBio for $1.8 billion

COPENHAGEN, Denmark & SEATTLE--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. announced today that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction. ProfoundBio is a privately-owned clinical-stage biotechnology company developing next-generation ADCs and ADC technologies for the treatment of certain cancers, including ovarian cancer and other FRα-expressing solid tumors. Genmab will acquire ProfoundBio for USD.

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.  The share buy-back program was expected to be completed no later than March 15, 2024, and comprised up to 190,000 shares.

Completion of share buy-back program

Company Announcement Repurchase of up to DKK 3.5 billion worth of shares Completion expected no later than December 16, 2024 COPENHAGEN, Denmark; March 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No.

Genmab Announces Initiation of Share Buy-Back Program

Company Announcement COPENHAGEN, Denmark; March 13, 2024 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 13, 2024, the Company's Board of Directors met to constitute itself. Ms. Deirdre P.

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement At Genmab A/S' Annual General Meeting held today March 13, 2024, the Annual Report for 2023 was approved Discharge was given to the Board of Directors and the Executive Management and the year's profit was carried forward The 2023 Compensation Report was approved Six members of the Board of Directors were re-elected Deloitte was elected as the new auditor of the Company The proposal from the Board of Directors on the Board of Directors' remuneration for 2024, the proposal to adopt an indemnification scheme, the proposal on a new Remuneration Policy, the proposal to acquire treasury shares and the proposals to amend Article 4A, Article 5, Article 5A and Article 5B and to enter a new Article 14 in the Articles of Association were adopted COPENHAGEN, Denmark; March 13, 2024 –  Genmab A/S  (Nasdaq: GMAB) held its Annual General Meeting, today at the Copenhagen Marriott Hotel, Copenhagen, Denmark. At the meeting, Deirdre P.

Passing of Genmab A/S' Annual General Meeting

Company Announcement COPENHAGEN, Denmark; March 11, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.

Transactions in connection with share buy-back program

AbbVie

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The FDA grants Priority Review to invest.

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

Company Announcement COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 316,899 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 13, 2024 COPENHAGEN, Denmark; February 15, 2024 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 13, 2024, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark.   The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed new Remuneration Policy is attached.

Notice to Convene the Annual General Meeting of Genmab A/S

Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript

Media Release COPENHAGEN, Denmark; February 14, 2024 Genmab filed Form 20-F for the financial year 2023 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2023 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2023. Both reports are available via the SEC's website, www.sec.gov and Genmab's website, www.genmab.com.

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the financial outlook for 2024.

Genmab Publishes 2023 Annual Report

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for review the marketing authorization application (MAA) of tisotumab vedotin, an antibody-drug conjugate (ADC), developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. If approved, tisotumab vedotin would be the first ADC granted European Union.

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Genmab's appeal against Johnson & Johnson in an arbitration case has been denied, eliminating the potential upside for the company. Despite this setback, Genmab remains well positioned to create shareholder value through continued revenue growth and pipeline progression and expansion. The launch of Epkinly/Tepkinly and the growth of other products are expected to reduce Genmab's reliance on Darzalex royalties.

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Company Announcement Net sales of DARZALEX® in 2023 totaled USD 9,744 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO ® in the U.S.), as reported by Johnson & Johnson were USD 9,744 million in 2023. Net trade sales were USD 5,277 million in the U.S. and USD 4,467 million in the rest of the world.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023

Company Announcement COPENHAGEN, Denmark; January 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the appeal arbitrator in its second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab has denied Genmab's appeal. As a result, the dismissal of Genmab's claims in the second arbitration is now concluded.

Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen

After losing some value lately, a hammer chart pattern has been formed for Genmab A/S Sponsored ADR (GMAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Bank of New York Mellon

PagSeguro Digital

Royal Philips

Skyward Specialty Insurance Group Inc

SKWD, PHG, BK, PAGS and GMAB have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2024.

New Strong Buy Stocks for January 17th

Genmab is a leading contender in the biotech industry with innovative technology, a robust pipeline, and strategic collaborations. Epcoritamab's growth is a positive trend to monitor, as it has shown impressive financial performance and secured regulatory approvals in multiple regions. DARZALEX, Genmab's flagship product, continues to be a substantial revenue driver, and investors should monitor its clinical programs for potential growth.

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Pfizer

NEW YORK & COPENHAGEN, Denmark--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy. The application has been granted P.

News for Genmab - ADR Stock (GMAB)